Tim van den Hooven
Overview
Explore the profile of Tim van den Hooven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
22
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061253
In the original article [...].
2.
Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, et al.
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33066704
The authors would like to make a correction to their published paper [...].
3.
van der Wel T, Hilhorst R, den Dulk H, van den Hooven T, Prins N, Wijnakker J, et al.
Nat Commun
. 2020 Jun;
11(1):3216.
PMID: 32587248
Chemical tools to monitor drug-target engagement of endogenously expressed protein kinases are highly desirable for preclinical target validation in drug discovery. Here, we describe a chemical genetics strategy to selectively...
4.
Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, et al.
Cancers (Basel)
. 2020 Feb;
12(2).
PMID: 32098410
Mitogen-activated protein kinase (MAPK) inhibition with the combination of BRAF (Rapidly Accelerated Fibrosarcoma) and MEK (Mitogen-activated protein kinase kinase) inhibitors has become the standard of first-line therapy of metastatic melanoma...